Improvement in the efficiency of adenovirus-mediated (morphometry: 13.2 ± 1.3% versus 4.1 ± 0.4% transfected arterial gene transfer may augment the utility of cardiomedial cells, P = 0.0001; chemiluminescence: 1.4 ± 0.2 vascular gene therapy. In vitro studies suggest that poloxversus 0.4 ± 0.2 mU ␤-galactosidase/mg protein, P = amer 407 enhances transfection efficiency of adenoviral 0.004). Moreover, in the presence of poloxamer 407, it was vectors in vascular smooth muscle cells. The aim of the possible to reduce the incubation time of adenoviral vecpresent study was to investigate whether poloxamer 407 tors from 20 to 10 min without compromising transfection facilitates adenovirus-mediated arterial transfection in vivo efficiency. Poloxamer 407 did not evoke specific tissue toxas well. Gene transfer was performed in balloon-injured rat icity. Site-specificity of arterial gene transfer, assessed by carotid arteries using E1− adenoviral vectors diluted in PCR, was not altered by administration of poloxamer 407. either poloxamer 407 or phosphate buffered saline (PBS).
Introduction
arteries. 2, 10, 11, 16 The relative resistance of atherosclerotic Arterial smooth muscle cells play a key role in arterial arteries to adenovirus-mediated transfection, however, diseases. 1 In the case of restenosis following balloon angimay constitute a major limitation of adenovirus-based oplasty, arterial injury is thought to trigger a phenotypic strategies to prevent restenosis in humans. 14, 17 modulation of medial smooth muscle cells which Various strategies designed to improve the efficiency migrate, proliferate, and secrete abundant extracellular of adenovirus-mediated arterial gene transfer have been matrix within the neointima, resulting in restenosis in evaluated in previous investigations. These include more approximately 30% of patients. The failure of pharmacoprotracted contact between the adenoviral vector and the logical attempts to prevent restenosis, to date, has arterial wall. 18 The principal drawback of this strategy, prompted development of molecular strategies based on however, is that most currently available delivery systhe introduction of antiproliferative genes into arterial tems require temporary arterial occlusion for gene transsmooth muscle cells at the angioplasty site. Because cell fer which may amplify the magnitude of myocardial division is ultimately controlled by intranuclear events, ischemia. 19, 20 Alternatively, increasing the concentration the protein products of genes selected for their antiproof adenoviral solutions results in dose-dependent liferative effects typically remain intracellular. 2 Conseincrease in transfection efficiency. 15 High adenoviral conquently, the success of arterial gene therapy in the case centrations, however, induce acute tissue toxicity.
21
of restenosis is likely to depend upon the proportion of Modifications in instrumentation employed for catheter smooth muscle cells expressing the transgene at the angidelivery have also been studied, 9, 12 but to date have had oplasty site, ie the transfection efficiency. 3 only a modest impact on augmenting transfection Recombinant adenoviruses are the most efficient efficiency. vectors currently available for arterial gene transfer in A new approach was recently suggested by March et vivo, [3] [4] [5] [6] and vascular smooth muscle cells represent the al, 22 who demonstrated that transfection efficiency was main target of adenovirus-mediated arterial transfecsignificantly improved when bovine as well as porcine tion. 2, [7] [8] [9] [10] [11] [12] [13] [14] [15] Transfection efficiencies achieved in porcine aortic smooth muscle cells were incubated with adenoand murine models using adenoviral vectors appear viral particles in the presence of poloxamer 407, a biocompatible polyoxyethyl-polyoxypropyl block co-polymer. [23] [24] [25] Accordingly, the current study was designed to investigate whether in vitro facilitation of adenovirus-poloxamer 407 could be extended to an in vivo model of cross-sections ( Figure 3 ). In arteries transfected using the Ad-RSV␤gal vector diluted in poloxamer 407 (n = 7, 170 arterial gene transfer. Gene transfer was performed in the balloon-injured rat carotid artery using E1− adenoviral cross-sections) 13.2 ± 1.3% of medial cells (range 0-50.6) expressed the transgene representing 43.3 ± 4.6 medial vectors expressing a nuclear-targeted ␤-galactosidase (Ad-RSV␤gal) or a firefly luciferase (Ad-CMVLuc) cells per arterial section (range 0-208). In contrast, in arteries transfected using Ad-RSV␤gal diluted in PBS (n reporter gene. Adenoviral particles were diluted in either poloxamer 407 or phosphate-buffered saline (PBS). The = 7, 144 cross-sections) gene transfer was detected in 4.1 ± 0.4% of medial cells (range 0-15.7) representing data demonstrate that transfection efficiency 3 days following gene transfer is significantly higher in rats trans-10.1 ± 0.8 medial cells per arterial section (range 0-27).
The percentage as well as the absolute number of transfected using adenovirus/poloxamer 407 versus adenovirus/PBS solutions, with neither incremental fected medial smooth muscle cells were significantly higher (P = 0.0001) when poloxamer 407 rather than PBS inflammation nor viral dissemination related to poloxamer 407. In addition, co-delivery of poloxamer 407 was used as vehicle for Ad-RSV␤gal. allows for shorter adenovirus incubation times. Such a strategy may be particularly valuable for clinical appliChemiluminescent assay cations of arterial gene therapy in which high transfection High ␤-galactosidase activity (typically 50-to 100-fold efficiencies are required and prolonged incubation times over background) was detected in nuclear extracts premay be hazardous.
pared from all arteries (14 of 14, 100%) 3 days following local delivery of Ad-RSV␤gal, whereas light emission generated by nuclear extracts from control arteries was
Results
below that produced by 7.5 mU of ␤-galactosidase and therefore considered undetectable. As shown in Figure 4 , Morphometric analyses nuclear ␤-galactosidase activity was significantly higher Nuclear ␤-galactosidase activity was detected in all when poloxamer 407 (1.4 ± 0.2 mU/mg protein) rather arteries (14 of 14, 100%) transfected using Ad-RSV␤gal 3 than PBS (0.4 ± 0.2 mU/mg protein) was used as vehicle days following gene transfer. On gross examination, for Ad-RSV␤gal (P = 0.004). intense blue staining, indicative of ␤-galactosidase activity, was present over the length of the transfected Optimization of poloxamer 407 concentration segment (Figures 1a and b) . Microscopic examination of To determine the optimal poloxamer 407 concentration, cross-sections from transfected arteries revealed almost 13 additional animals were transfected using Adcomplete endothelial denudation with some remaining RSV␤gal diluted in either PBS (n = 4) or various poloxendothelialized sections near the proximal and distal amer 407 concentrations (5%, n = 3; 15%, n = 3; and 30%, ligatures of the transfected segment. These endon = 3). Transfection efficiency, expressed as nuclear ␤-thelialized cross-sections represented less than 5% of total galactosidase activity, was significantly higher (P Ͻ 0.05) arterial sections in both groups. No detectable coating in the 15% group (1.6 mU/mg protein) than in the 5% was observed on the abluminal aspect of arteries trans-(0.4 ± 0.1 mU/mg protein) and the PBS (0.2 ± 0.1 mU/mg duced using Ad-RSV␤gal diluted in poloxamer 407. protein) groups. Transfection efficiency was slightly, but Transfected cells were located in superficial as well as not significantly higher in the 5% group than in the PBS deeper cell layers of the media in de-endothelialized secgroup. All arteries (three of three) in which a 30% soltions, below an intact internal elastic lamina (Figure 1c ution of poloxamer 407 was used were thrombosed at f), whereas gene transfer was strictly limited to the endodeath, precluding measurement of transfection efficiency thelium in endothelialized sections (data not shown). The in these arteries. number of cross-sections showing evidence of nuclear ␤-galactosidase activity was significantly higher in carotid arteries transfected using a solution of Ad-RSV␤gal
Influence of incubation time on transfection efficiency In 20 additional animals, gene transfer was performed diluted in poloxamer 407 (172 of 252) rather than in PBS (118 of 252, P = 0.0001). Immunostaining with a monousing the Ad-CMVLuc vector diluted in either 15% poloxamer 407 or PBS. Four groups were compared clonal antibody specific to smooth muscle ␣-actin identified transfected cells in the media as vascular smooth (n = 5 in each group): 20-min incubation/15% poloxamer 407, 10-min incubation/15% poloxamer 407, 20-min muscle cells (Figure 2) . No ␤-galactosidase activity was detected in control arteries. As previously described, 15 incubation/PBS, 10-min incubation/PBS. For each incubation time, transfection efficiency, expressed as relative evidence of mild, injury-related coagulation necrosis of medial smooth muscle cells was observed in almost all light units (RLU)/mg protein, was significantly higher (P Ͻ 0.05) in the poloxamer 407 groups than in the PBS balloon-injured left carotid arteries (either transfected using Ad-RSV␤gal or the control vector Ad-RSVapoA1; groups ( Figure 5 ). Moreover, there was a time-dependent decrease in transfection efficiency when incubation time or untransfected). Severely injured arterial sections, arbitrarily defined as those sections in which total medial cell was reduced from 20 to 10 min in the poloxamer 407 (1911 × 10 3 RLU/mg, P Ͻ 0.05) groups. Of interest, (roughly 350 medial cells per section), were excluded from morphometric analysis; indeed, these sections have a lesser reduction in luciferase activity was noted when poloxamer 407 (2.6-fold) rather than PBS (22.5-fold) was a lower cellularity which may spuriously increase the percentage of transduced cells.
used as a diluant for Ad-CMVLuc, resulting in similar transfection efficiencies in the 10 min/poloxamer 407 and Transfection efficiency was determined quantitatively by counting stained versus total medial nuclei on arterial the 20 min/PBS groups.
Figure 1 Arterial gene transfer in rat carotid arteries in vivo. Ad-RSV␤gal was diluted in either 15% poloxamer 407 (a, c, e) or PBS (b, d, f). ␤-Galactosidase activity was assessed 3 days following gene transfer using X-gal staining. ␤-Galactosidase activity (blue stain) is more intense in arteries transfected using the Ad-RSV␤gal/poloxamer 407 versus Ad-RSV␤gal/PBS solutions. (a) and (b) Gross examination. (c-f) Microscopic examination. Transfected cells (nuclear blue stain) are located in the media. Adjacent sections are counter-stained using hematoxylin-eosin (c, d) or elastic trichrome (e, f).
Influence of poloxamer 407 pre-treatment on CMVLuc diluted in PBS. Luciferase activity was similar in the two pre-treated groups (950 × 10 , respectively, NS). When compared with 10 rats transduced using improved transfection efficiency achieved using co-delivery of poloxamer 407 and adenoviral vectors could be co-delivery of poloxamer 407 (n = 5) or PBS (n = 5) with Ad-CMVLuc (20-min incubation), there was no difference reproduced when poloxamer 407 and adenoviral particles were used sequentially as follows: (1) balloon between luciferase activities in the two pre-treated groups and the PBS co-delivery group (833 × injury; (2) 10-min pre-treatment with 15% poloxamer 407 (n = 2) or PBS (n = 2); (3) 20-min incubation with Ad-10 3 ± 66 × 10 3 RLU/mg protein). However, luciferase , P Ͻ 0.05) than in (one of two). The intensity of the inflammatory reaction was highly variable among animals, as well as among the two pre-treated groups. These results suggest that poloxamer 407 augments the efficacy of gene transfer arterial cross-sections retrieved from the same animal. Typically, macrophages accumulated in proximity to foci only if co-delivered with adenoviral particles. of transfected cells (Figure 6a and b) . This pattern conExtra-arterial transfection No histochemical evidence of nuclear ␤-galactosidase trasted with the finding of a more extensive transmural inflammatory cell infiltrate invading all layers of the activity was found in tissue samples from the liver, brain, testis, lung, myocardium and kidney. As shown in Figure  artery wall, in which case no blue nuclei were observed (Figure 6c ). In contrast, no inflammatory infiltrate was 7, PCR analysis designed to amplify specifically the recombinant ␤-galactosidase gene disclosed no evidence detected in injured and sham-transfected left carotid arteries (n = 3) or uninstrumented right carotid arteries of extra-arterial adenoviral genome in these same tissues. (n = 21).
Discussion
The results of the present study indicate that poloxamer 407 potentiates adenovirus-mediated gene transfer to denuded rat carotid arteries in vivo with neither additional tissue toxicity nor adenovirus dissemination.
Two different methods were used to quantify transfection efficiency. Morphometric analysis indicates a threeto four-fold increase in the percentage as well as absolute number of transfected medial smooth muscle cells when poloxamer 407 rather than PBS is used as vehicle for recombinant adenoviruses. This was paralleled by an approximately three-fold increase in transgene expression (either nuclear ␤-galactosidase or luciferase activity) in the poloxamer 407-treated animals. The results of our optimization study suggest that optimal arterial transduction is achieved using a 15% poloxamer 407 solution.
Poloxamer 407 has been used to achieve parenteral sustained release of interleukin-2, 26 as well as urease.
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Recently, successful inhibition of intimal hyperplasia has been reported in balloon-injured rat carotid arteries using periadventitial delivery of a poloxamer 407 gel containing anti-c-myb antisense oligonucleotides, 28 as well as dominant negative mutants of the gene encoding ras protein. 29 Periadventitial delivery, however, requires direct exposure of the vessel. By contrast, the endoluminal route used in the present report to introduce the adenovirus/poloxamer 407 solution in the arterial lumen is more amenable to percutaneous delivery, and therefore clinically applicable.
Improvement in the efficiency of adenovirus-based arterial gene transfer using poloxamer 407 has several potential advantages. First, expression of a transgene in a higher percentage of cells is likely to enhance the biological effect of the transgene product. This is particularly true: (1) if the transgene product is not transmitted to neighboring cells, through either active secretion or 'bystander effect', and thereby modifies only cells which are successfully transduced, a feature characteristic of most candidate genes proposed to inhibit restenosis; 3 or (2) if the target arterial segment is severely atherosclerotic, a condition which has been reported to limit adenovirus-mediated arterial transfection.
14,17 Second, relatively long incubation times (20-30 min) are required to achieve efficient arterial gene transfer using adenoviral vectors, 7, 9, 12, 14, 15, 30 and attempts to shorten incubation times have resulted in significantly lower transfection efficiencies. 18 March et al 22 reported that cellular uptake of adenoviruses by vascular smooth muscle cells in vitro fection efficiency similar to that achieved using a 20-min incubation of Ad-CMVLuc alone. Thus, the use of poloxamer 407 reduces the time of blood flow interruption required for adenovirus incubation and may limit the potential for ischemic injury induced by the transfection procedure itself.
Several mechanisms may facilitate adenovirusmediated arterial gene transfer by co-delivery of poloxamer 407 together with adenoviral particles. First, a small part of the adenovirus-loaded poloxamer 407 may coat the luminal aspect of the transfected artery and act as a transient local reservoir for sustained release of adenoviral vectors. In this case, improved transfection efficiency would result from a sustained exposure to adenoviral particles following restoration of blood flow. In our experiments, however, we were not able to detect an abluminal depot of poloxamer in transduced arteries, even in two animals killed early (30 min) following poloxamer delivery (data not shown). Alternatively, a direct interaction between poloxamer 407 and the smooth muscle cell membrane may accelerate adenovirus uptake by smooth muscle cells and thereby alter the susceptibility of these cells to adenovirus transfection. A specific interaction between poloxamer 407 and arterial cells has been suggested by previous reports showing that poloxamer 407 redirects intravenously injected microspheres, the size of which (60-250 nm) is similar to that of adenoviral particles (approximately 100 nm in diameter), to sinusoidal endothelial cells of bone marrow.
23- 25 The recent finding by March et al 22 that poloxamer 407 increases the rate of smooth muscle cell transfection by adenoviral vectors, ie the number of transfection events per unit time of exposure to the adenoviral particles, favors the latter hypothesis. Our results are in agreement with these in vitro data, in that luciferase activity detected following a 10-min incubation of Ad-CMVLuc averaged approximately 39% of luciferase activity measured following a 20-min incubation in presence of poloxamer 407 versus only approximately 5% in the presence of PBS, suggesting an increased rate of transfection related to poloxamer 407. In addition, our finding that potentiation of transfection efficiency occurred only when poloxamer 407 was co-delivered with adenoviral particles, whereas pretreatment with poloxamer 407 before gene transfer did not improve transfection efficiency, suggests that poloxamer 407 facilitates cellular uptake of adenoviral particles as well.
Finally, no specific toxicity was detected in poloxamer 407-treated animals. Inflammatory infiltrates were observed, 3 days following gene transfer, in arteries transfected using the adenovirus/poloxamer 407 (seven In summary, the present study demonstrates that poloxamer 407, formulated as a 15% gel, enhances transfection efficiency following intraluminal delivery of adenoviral vectors in vivo and allows for reduced incucarotid arteriotomy, allowed to incubate for 10-20 min, then removed by aspiration before restoration of blood bation times. Poloxamer 407 may therefore be useful as an adjunct for adenovirus-mediated arterial gene transflow to prevent viral wash-out. Uninstrumented right carotid arteries (n = 81), balloon-injured left carotid fer. This strategy may be particularly valuable for those indications in which transfection efficiency is hampered arteries transfected using the control vector Ad-RSVapoA1 diluted in poloxamer 407 (n = 4) or PBS (n = 4), by a nonsecreted, intracellular transgene product and/or complex atherosclerotic plaque.
and balloon-injured and sham-transfected left carotid arteries (poloxamer 407 alone: n = 2; PBS alone: n = 2; adenovirus storage buffer: n = 2) were used as controls.
Materials and methods

Transfection efficiency Recombinant adenoviruses
Rats were killed 3 days following gene transfer by pentoThree recombinant adenoviral vectors, all prepared from barbital overdose. Gene transfer was assessed by both human adenovirus 5 serotype, were used in this study.
morphometric and chemiluminescent analyses in animals These vectors are deleted of E1a (as well as part of E1b transfected using the Ad-RSV␤gal vector and chemilumiand E3), thus are replication defective. Ad-RSV␤gal was nescent analysis alone in animals transfected using the constructed, grown, and purified as previously Ad-CMVLuc vector: described. [32] [33] [34] It includes an expression cassette for a variant of E. coli ␤-galactosidase gene (nlslacZ), encoding
Morphometric analyses: Venous drainage was estaba nuclear-targeted ␤-galactosidase under the control of lished through bilateral jugular venotomies. Both carotid the Rous sarcoma virus long terminal repeat promoter.
arteries were perfused with PBS via a cannula inserted Ad-CMVLuc was generated by homologous recombiinto the left ventricle until the effluent became grossly nation in 293 cells between an incomplete adenovirus 5 clear of blood. An additional 5 min perfusion-fixation at genome and a firefly luciferase-expressing shuttle plas-90 mmHg with 1% paraformaldehyde was then performid containing CMV enhancer/promoter sequences. Admed. Carotid arteries were harvested and fixed further by RSVapoA1 (courtesy of Dr Patrick Benoit, Rhô ne-Poulimmersion in the same fixative for 5 min. ␤-Galactosidase enc-Rorer/Gencell, Vitry, France) contains an apolipoactivity was assessed by incubating arteries in X-gal chroprotein A1 gene under the control of the Rous sarcoma magen (Boehringer Mannheim, Indianapolis, IN, USA) virus long terminal repeat promoter and was used in confor 2 h at 37°C, as previously reported. 12, 14, 36 After staintrol experiments. The titers of adenoviral preparations ing, arteries were rinsed in saline, photographed through were established by plaque-assay on 293 cells. Viral a dissecting microscope, and sectioned into three serial stocks, diluted to titers of 10 11 p.f.u./ml of storage buffer 5-mm-long rings. The rings were subsequently embed-(10 mmol/l Tris-HCl, pH 7.5; 1 mmol/l MgCl 2 ; 135 ded in paraffin, and 12 6-m-thick sections were cut from mmol/l NaCl; 10% glycerol), were stored at −80°C and each ring at six different levels throughout the entire thawed on ice 5 min before use.
length of the ring, representing more than 25 000 cells per artery. Arterial sections were counterstained with hematoxylin and eosin or Richardson's elastic-trichrome, and Arterial gene transfer Seventy-nine Sprague-Dawley rats weighing 400-500 g examined through a light microscope. Expression of transfected nlslacZ gene was considered positive only were studied. The investigation conforms with the Guide for the care and use of laboratory animals published by the when dark blue nuclear staining was observed. In each arterial section, transfection efficiency was determined as US National Institutes of Health (NIH publication No 85-23, revised 1985). Animals were anesthetized with an the percentage of stained versus total medial cells. intraperitoneal injection of sodium pentobarbital (60 mg/kg). Arterial gene transfer was performed in the balMeasurement of nuclear ␤-galactosidase activity: To assess further the amount of recombinant nuclear ␤-loon-injured left common carotid artery. Injury of the common carotid artery was performed using three passgalactosidase produced in transfected arteries, ␤-galactosidase activity was measured using a chemiluminescent ages of an inflated 2F Fogarty balloon catheter (Baxter Healthcare, Mundelein, IL, USA) introduced through an assay (Galacto-Light, Tropix, Bedford, MA, USA) in nuclear extracts prepared from both carotid arteries as arteriotomy performed in the external carotid artery as previously described.
35 Immediately following arterial previously described. 14 Light emission was measured using a Lumat LB 9501 luminometer (Berthold, Nashua, injury, a 15-mm long segment of the common carotid artery was isolated between two temporary ligatures NH, USA). The assay was calibrated with a standard curve generated by using purified E. coli ␤-galactosidase placed on the proximal segments of the common and internal carotid arteries. Aliquots of recombinant adeno-(Boehringer Mannheim, specific activity 300 U/mg). The calibration curve was linear from 7.5-7500 mU of ␤-viruses were diluted immediately before use to a total volume of 50 l in either PBS or a solution of 15% poloxgalactosidase. When light emission was below that produced by 7.5 mU, ␤-galactosidase activity was arbitrarily amer 407 (Lutrol F127; BASF, Levallois, France). Concentrated to this extent, poloxamer 407 is a liquid at 4°C and considered undetectable. All reactions were performed in triplicate. The mean of the three values was used to measturns into a viscous gel at body temperature. Final concentrations of adenoviral solutions (Ad-RSV␤gal: 2 × 10 10 ure total nuclear ␤-galactosidase activity per vessel. Protein content in the nuclear extract was measured using p.f.u./ml; Ad-CMVLuc: 5 × 10 10 p.f.u./ml) have been shown to achieve both optimal transfection efficiency and the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Transfection efficiency was expressed as nuclear ␤-low arterial toxicity in the same animal model. 15 Adenoviral solutions were infused into the isolated arterial galactosidase activity normalized to the nuclear protein content. segment via a cannula introduced through the external It has been reported that the development of an inflammatory response to adenoviral proteins may comas previously described. 37 Briefly, carotid arteries were homogenized in 1 ml 1 × cell culture lysis reagent. The plicate in vivo introduction of adenoviral vectors into mammalian tissues. 15, 38 To evaluate further the presence homogenate was spun for 5 min to pellet large debris. A 10-l aliquot of the supernatant was then mixed with 50 of an inflammatory infiltrate in adenoviral transfected arteries, additional immunohistochemical studies were l of luciferase assay reagent at room temperature and inserted in the luminometer. Light emission was measperformed on three to six sections from each arterial ring using a monoclonal primary antibody specific for macroured in triplicates over 10 s and expressed as RLUs. Background noise was measured in samples consisting only phages (RAM-11; Dako, Carpinteria, CA, USA). of cell culture lysis and luciferase assay reagents; all such analyses produced 0 RLU. The specimen's total luciferase Detection of extra-arterial transfection In six rats transfected using Ad-RSV␤gal diluted in 15% activity was derived from the mean of the aliquot results.
The RLU values obtained were within the linear range of poloxamer 407 (n = 3) or PBS (n = 3), tissue samples from the liver, brain, testes, lung, myocardium and kidney a dilution curve established using purified firefly luciferase (Sigma Chemical, St Louis, MO, USA). Total protein were harvested immediately after death. For each specimen, nlslacZ gene presence and expression were assessed content in each artery was determined using the Bio-Rad assay, and transfection efficiency was expressed as by polymerase chain reaction (PCR) and histochemistry (X-gal), respectively. luciferase activity normalized to the total protein content.
Optimization of poloxamer 407 concentration PCR protocol: The PCR protocol used in this study has been previously described. 12 Briefly, DNA was extracted The influence of poloxamer 407 concentration on transfection efficiency was studied in 13 rats in which arterial from tissues by standard techniques. DNA amplification was carried out using oligonucleotide primers designed gene transfer was performed using the Ad-RSV␤gal vector (incubation time: 20 min) diluted in either PBS (n = to selectively amplify Ad-RSV␤gal DNA over the endogenous ␤-galactosidase gene by using primers 4) or poloxamer 407 at the following concentrations: 5% (n = 3), 15% (n = 3) and 30% (n = 3). Transfection complementary to the adenovirus sequence coding for protein 9 and the nlslacZ gene. Amplification products efficiency was expressed as nuclear ␤-galactosidase activity/mg protein 3 days after gene transfer.
were detected on 1% agarose gel stained with ethidium bromide as a 700-bp fragment. It was determined by spiking experiments that this protocol could detect one copy Influence of incubation time on transfection efficiency In 20 animals, the Ad-CMVLuc vector was used to study of the adenoviral genome in 10 4 cells. the impact of the incubation time upon transfection efficiency. Two incubation times were studied: 20 min (n Histochemistry: Each tissue specimen was also processed for X-gal staining. For each specimen, two samples = 10) and 10 min (n = 10). In each group, Ad-CMVLuc was diluted in either PBS (n = 5) or 15% poloxamer 407 weighing approximately 300 mg were obtained, embedded in paraffin, and cut into six 6-m-thick sections. Sec-(n = 5). Luciferase activity was measured 3 days after gene transfer.
tions were counterstained with hematoxylin and eosin, and examined by light microscopy for the presence of dark blue nuclei indicative of nlslacZ gene expression. In Influence of poloxamer 407 pre-treatment on transfection efficiency each organ, between 10 4 and 10 5 cells were examined. To investigate whether poloxamer 407 pre-treatment of the arterial wall per se impacts upon transfection Summary of gene transfer experiments Seventy-nine rats were studied. In each experiment, gene efficiency of adenoviral vectors, gene transfer was performed in four additional animals as follows. Balloon injury transfer was performed in the left carotid artery following endothelium abrasion in order to target medial vascuwas performed as described previously. Then, 15% poloxamer 407 alone (n = 2) or PBS (n = 2) were incubated lar smooth muscle cells. Transfection efficiency was measured 3 days following gene transfer. in the left carotid artery for 10 min, then retrieved and the artery was flushed twice with saline. Gene transfer
The impact of poloxamer 407 upon transfection efficiency of adenoviral vectors was studied in 28 animals was subsequently performed in the pre-treated arterial segment using a 20-min incubation of the Ad-CMVLuc which were transduced using Ad-RSV␤gal diluted in either 15% poloxamer 407 (n = 14) or PBS (n = 14). In 14 vector diluted in PBS. Luciferase activity was measured 3 days following gene transfer and compared with that control animals, the left carotid artery was ballooninjured and either sham-transfected (15% poloxamer 407: achieved in 10 animals in which 15% poloxamer 407 (n = 5) or PBS (n = 5) were co-incubated with Ad-CMVLuc n = 2; PBS: n = 2; adenovirus storage buffer: n = 2), or transfected using the control adenovirus Ad-RSVapoA1 for 20 min.
diluted in 15% poloxamer 407 (n = 4) or PBS (n = 4). Optimal poloxamer 407 concentration was determined in 13 Immunohistochemical studies To determine the nature of transduced cells in the arterial animals transduced using Ad-RSV␤gal diluted in increasing concentrations of poloxamer 407 (ranging from 5 to wall, immunohistochemical staining of X-gal-stained arterial sections was performed using a mouse mono-30%). The influence of the incubation time on transfection efficiency was investigated in 20 animals in which Adclonal primary antibody specific for smooth muscle ␣-actin (HHF-35; Enzo Diagnostics, Farmingdale, NY, USA)
CMVLuc was incubated for 20 (n = 10) or 10 min (n = 10); for each incubation time, Ad-CMVLuc was diluted and a polyclonal peroxidase-labeled anti-mouse immuno-
